Published in Mutat Res on September 18, 2006
The linear no-threshold relationship is inconsistent with radiation biologic and experimental data. Radiology (2009) 3.25
The dose window for radiation-induced protective adaptive responses. Dose Response (2009) 1.11
The new radiobiology: returning to our roots. Dose Response (2012) 0.85
No Evidence for the In Vivo Induction of Genomic Instability by Low Doses of CS Gamma Rays in Bone Marrow Cells of BALB/CJ and C57BL/6J Mice. Dose Response (2011) 0.84
The role of dose rate in radiation cancer risk: evaluating the effect of dose rate at the molecular, cellular and tissue levels using key events in critical pathways following exposure to low LET radiation. Int J Radiat Biol (2016) 0.80
A single whole-body low dose X-irradiation does not affect L1, B1 and IAP repeat element DNA methylation longitudinally. PLoS One (2014) 0.79
Adaption By Low Dose Radiation Exposure: A Look at Scope and Limitations for Radioprotection. Dose Response (2015) 0.78
Non-problematic risks from low-dose radiation-induced DNA damage clusters. Dose Response (2008) 0.78
Is the Linear No-Threshold Dose-Response Paradigm Still Necessary for the Assessment of Health Effects of Low Dose Radiation? J Korean Med Sci (2016) 0.76
Requirements for identification of low dose and non-linear mutagenic responses to ionising radiation. Dose Response (2007) 0.76
Low-dose or low-dose-rate ionizing radiation-induced bioeffects in animal models. J Radiat Res (2017) 0.75
Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. Endocr Relat Cancer (2004) 3.03
Peptidomimetic targeting of critical androgen receptor-coregulator interactions in prostate cancer. Nat Commun (2013) 2.11
Distinct nuclear receptor expression in stroma adjacent to breast tumors. Breast Cancer Res Treat (2013) 2.05
Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. Cancer Res (2009) 1.98
Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors. Clin Cancer Res (2012) 1.78
Structural and functional consequences of glutamine tract variation in the androgen receptor. Hum Mol Genet (2004) 1.74
Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1. EMBO J (2011) 1.72
Dual roles of PARP-1 promote cancer growth and progression. Cancer Discov (2012) 1.63
A gene signature identified using a mouse model of androgen receptor-dependent prostate cancer predicts biochemical relapse in human disease. Int J Cancer (2012) 1.60
Importance of minimal residual disease testing during the second year of therapy for children with acute lymphoblastic leukemia. J Clin Oncol (2003) 1.57
Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors. Cell Cycle (2012) 1.54
Androgen receptor activity at the prostate specific antigen locus: steroidal and non-steroidal mechanisms. Mol Cancer Res (2003) 1.49
Breast and prostate cancer: more similar than different. Nat Rev Cancer (2010) 1.48
Discovery of circulating microRNAs associated with human prostate cancer using a mouse model of disease. Int J Cancer (2011) 1.46
Formation of hyaluronan- and versican-rich pericellular matrix by prostate cancer cells promotes cell motility. J Biol Chem (2007) 1.42
IκBα mediates prostate cancer cell death induced by combinatorial targeting of the androgen receptor. BMC Cancer (2016) 1.39
Radiation-induced bystander effects: what are they, and how relevant are they to human radiation exposures? Radiat Res (2011) 1.39
"Fear of radiation" is frightening. Australas Phys Eng Sci Med (2010) 1.38
The contribution of different androgen receptor domains to receptor dimerization and signaling. Mol Endocrinol (2008) 1.32
Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation. Mol Cancer Ther (2007) 1.32
The linear no-threshold model does not hold for low-dose ionizing radiation. Radiat Res (2004) 1.25
Control of androgen receptor signaling in prostate cancer by the cochaperone small glutamine rich tetratricopeptide repeat containing protein alpha. Cancer Res (2007) 1.20
Expression of extracellular matrix components versican, chondroitin sulfate, tenascin, and hyaluronan, and their association with disease outcome in node-negative breast cancer. Clin Cancer Res (2004) 1.20
Circulating insulin-like growth factor-I and binding protein-3 and the risk of breast cancer. Cancer Epidemiol Biomarkers Prev (2007) 1.20
Disruption of androgen receptor signaling by synthetic progestins may increase risk of developing breast cancer. FASEB J (2007) 1.19
Circulating steroid hormone concentrations in postmenopausal women in relation to body size and composition. Breast Cancer Res Treat (2008) 1.19
Androgen receptor signaling: mechanism of interleukin-6 inhibition. Cancer Res (2004) 1.16
Circulating insulin-like growth factor-I and binding protein-3 and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev (2006) 1.15
Identification of novel androgen receptor target genes in prostate cancer. Mol Cancer (2007) 1.15
A potential autocrine role for vascular endothelial growth factor in prostate cancer. Cancer Res (2002) 1.14
Circulating steroid hormone levels and risk of breast cancer for postmenopausal women. Cancer Epidemiol Biomarkers Prev (2010) 1.12
Adaptive response for chromosomal inversions in pKZ1 mouse prostate induced by low doses of X radiation delivered after a high dose. Radiat Res (2007) 1.11
Variants in the prostate-specific antigen (PSA) gene and prostate cancer risk, survival, and circulating PSA. Cancer Epidemiol Biomarkers Prev (2006) 1.07
Comparative biomarker expression and RNA integrity in biospecimens derived from radical retropubic and robot-assisted laparoscopic prostatectomies. Cancer Epidemiol Biomarkers Prev (2010) 1.07
Global levels of specific histone modifications and an epigenetic gene signature predict prostate cancer progression and development. Cancer Epidemiol Biomarkers Prev (2010) 1.05
Sensitive and specific measurement of minimal residual disease in acute lymphoblastic leukemia. J Mol Diagn (2009) 1.03
Dynamic methylation of histone H3 at lysine 4 in transcriptional regulation by the androgen receptor. Nucleic Acids Res (2003) 1.03
Decreased androgen receptor levels and receptor function in breast cancer contribute to the failure of response to medroxyprogesterone acetate. Cancer Res (2005) 1.02
Modulation of prostate cancer cell attachment to matrix by versican. Cancer Res (2003) 1.02
Co-expression of the androgen receptor and the transcription factor ZNF652 is related to prostate cancer outcome. Oncol Rep (2010) 1.02
Circulating microRNAs: macro-utility as markers of prostate cancer? Endocr Relat Cancer (2012) 1.02
Ex vivo culture of human prostate tissue and drug development. Nat Rev Urol (2013) 1.00
Androgen receptor levels in prostate cancer epithelial and peritumoral stromal cells identify non-organ confined disease. Prostate (2005) 1.00
Elevated levels of HER-2/neu and androgen receptor in clinically localized prostate cancer identifies metastatic potential. Prostate (2008) 0.98
Research resource: nuclear receptors as transcriptome: discriminant and prognostic value in breast cancer. Mol Endocrinol (2013) 0.97
Sensitive quantitative analysis of murine LINE1 DNA methylation using high resolution melt analysis. Epigenetics (2012) 0.95
PC-3 cells with enhanced androgen receptor signaling: a model for clonal selection in prostate cancer. Prostate (2004) 0.94
Antiproliferative actions of the synthetic androgen, mibolerone, in breast cancer cells are mediated by both androgen and progesterone receptors. J Steroid Biochem Mol Biol (2008) 0.93
Determining the repertoire of IGH gene rearrangements to develop molecular markers for minimal residual disease in B-lineage acute lymphoblastic leukemia. J Mol Diagn (2009) 0.92
Hsp90: still a viable target in prostate cancer. Biochim Biophys Acta (2012) 0.92
DNA methylation of the ABO promoter underlies loss of ABO allelic expression in a significant proportion of leukemic patients. PLoS One (2009) 0.91
5alpha-Reductase type 2 gene variant associations with prostate cancer risk, circulating hormone levels and androgenetic alopecia. Int J Cancer (2007) 0.91
GRIP1 mediates the interaction between the amino- and carboxyl-termini of the androgen receptor. Biol Chem (2005) 0.90
Extremely low priming doses of X radiation induce an adaptive response for chromosomal inversions in pKZ1 mouse prostate. Radiat Res (2006) 0.90
Research resource: interplay between the genomic and transcriptional networks of androgen receptor and estrogen receptor α in luminal breast cancer cells. Mol Endocrinol (2012) 0.89
GSTP1 DNA methylation and expression status is indicative of 5-aza-2'-deoxycytidine efficacy in human prostate cancer cells. PLoS One (2011) 0.89
Apolipoprotein-D: a novel cellular marker for HGPIN and prostate cancer. Prostate (2004) 0.89
The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL. Int J Cancer (2006) 0.88
Constitutively-active androgen receptor variants function independently of the HSP90 chaperone but do not confer resistance to HSP90 inhibitors. Oncotarget (2013) 0.88
SGTA: a new player in the molecular co-chaperone game. Horm Cancer (2013) 0.86
Identification of androgen receptor splice variant transcripts in breast cancer cell lines and human tissues. Horm Cancer (2014) 0.85
A novel polymorphism in a forkhead box A1 (FOXA1) binding site of the human UDP glucuronosyltransferase 2B17 gene modulates promoter activity and is associated with altered levels of circulating androstane-3α,17β-diol glucuronide. Mol Pharmacol (2010) 0.85
An androgen receptor mutation in the MDA-MB-453 cell line model of molecular apocrine breast cancer compromises receptor activity. Endocr Relat Cancer (2012) 0.84
The dynamic and static modification of the epigenome by hormones: a role in the developmental origin of hormone related cancers. Biochim Biophys Acta (2009) 0.84
Expression and localization of homeodomain proteins DLX4, HB9 and HB24 in malignant and benign human colorectal tissues. Anticancer Res (2004) 0.83
Cancer-associated genes can affect somatic intrachromosomal recombination early in carcinogenesis. Mutat Res (2004) 0.83
Ski-interacting protein (SKIP) interacts with androgen receptor in the nucleus and modulates androgen-dependent transcription. BMC Biochem (2013) 0.83
Uranium dynamics and developmental sensitivity in rat kidney. J Appl Toxicol (2013) 0.83
Dose-dependent increase or decrease of somatic intrachromosomal recombination produced by etoposide. Mutat Res (2002) 0.83
Corepressor effect on androgen receptor activity varies with the length of the CAG encoded polyglutamine repeat and is dependent on receptor/corepressor ratio in prostate cancer cells. Mol Cell Endocrinol (2011) 0.83
Subdomain structure of the co-chaperone SGTA and activity of its androgen receptor client. J Mol Endocrinol (2012) 0.82
Low dose X-radiation adaptive response in spleen and prostate of Atm knockout heterozygous mice. Int J Radiat Biol (2007) 0.82
Immunohistochemical level of unsulfated chondroitin disaccharides in the cancer stroma is an independent predictor of prostate cancer relapse. Cancer Epidemiol Biomarkers Prev (2008) 0.82
A novel androgen receptor mutant, A748T, exhibits hormone concentration-dependent defects in nuclear accumulation and activity despite normal hormone-binding affinity. Mol Endocrinol (2002) 0.82
Uncoupling of hormone-dependence from chaperone-dependence in the L701H mutation of the androgen receptor. Mol Cell Endocrinol (2007) 0.82
Multiple nuclear receptor signaling pathways mediate the actions of synthetic progestins in target cells. Mol Cell Endocrinol (2011) 0.81
Protein arginine methyltransferase 6-dependent gene expression and splicing: association with breast cancer outcomes. Endocr Relat Cancer (2012) 0.81
A novel androgen receptor amino terminal region reveals two classes of amino/carboxyl interaction-deficient variants with divergent capacity to activate responsive sites in chromatin. Endocrinology (2009) 0.81
Extremely low doses of X-radiation can induce adaptive responses in mouse prostate. Dose Response (2007) 0.80
PRMT2 and RORγ expression are associated with breast cancer survival outcomes. Mol Endocrinol (2014) 0.79
Local gene transfer to modulate rat corneal allograft rejection. Invest Ophthalmol Vis Sci (2005) 0.79
Expression of Drosophila Ca2+ permeable transient receptor potential-like channel protein in a prostate cancer cell line decreases cell survival. Cancer Gene Ther (2003) 0.79
Androgen receptor protein levels are significantly reduced in serous ovarian carcinomas compared with benign or borderline disease but are not altered by cancer stage or metastatic progression. Horm Cancer (2013) 0.79
The methylation of DNA repeat elements is sex-dependent and temporally different in response to X radiation in radiosensitive and radioresistant mouse strains. Radiat Res (2014) 0.79
Knockdown of the cochaperone SGTA results in the suppression of androgen and PI3K/Akt signaling and inhibition of prostate cancer cell proliferation. Int J Cancer (2013) 0.79